S-8 1 d96543ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on February 23, 2021

Registration No. 333-_____

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Epizyme, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   26-1349956
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification No.)
400 Technology Square, 4th Floor
Cambridge, MA
   02139
(Address of Principal Executive Offices)   (Zip Code)

2013 Stock Incentive Plan

2013 Employee Stock Purchase Plan

(Full title of the plan)

Robert B. Bazemore

President and Chief Executive Officer

Epizyme, Inc.

400 Technology Square, 4th Floor

Cambridge, MA 02139

(Name and address of agent for service)

(617) 229-5872

(Telephone number, including area code, of agent for service)

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☒    Accelerated filer   ☐
Non-accelerated filer   ☐ (Do not check if a smaller reporting company)    Smaller reporting company   ☐
     Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

CALCULATION OF REGISTRATION FEE

 

 

Title of Securities to be Registered   Amount to be
Registered(1)		   Proposed Maximum
Offering Price Per
Share		   Proposed Maximum
Aggregate Offering
Price		   Amount of
Registration Fee

Common Stock, $0.0001 par value per share

   2,733,333 shares(2)   $10.62(3)   $29,027,996.46(3)   $3,166.95

 

 

(1)

In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

(2)

Consists of (i) 2,500,000 additional shares issuable under the 2013 Stock Incentive Plan and (ii) 233,333 additional shares issuable under the 2013 Employee Stock Purchase Plan.

(3)

Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated on the basis of $10.62, the average of the high and low price of the Registrant’s Common Stock as reported on the Nasdaq Global Select Market on February 16, 2021.

 

 

 

 

Statement of Incorporation by Reference

This Registration Statement on Form S-8 is filed to register the offer and sale of (i) an additional 2,500,000 shares of the Registrant’s common stock, $0.0001 par value per share, to be issued under the Registrant’s 2013 Stock Incentive Plan and (ii) an additional 233,333 shares of the Registrant’s common stock, $0.0001 par value per share, to be issued under the Registrant’s 2013 Employee Stock Purchase Plan. This Registration Statement incorporates by reference the contents of the registration statement on Form S-8, File No. 333-189629, filed by the Registrant on June 27, 2013, relating to the Registrant’s 2008 Stock Incentive Plan, 2013 Stock Incentive Plan and 2013 Employee Stock Purchase Plan; the registration statement on Form S-8, File No. 333-194205, filed by the Registrant on February 28, 2014, relating to the Registrant’s 2013 Stock Incentive Plan and 2013 Employee Stock Purchase Plan, except for Item 8, Exhibits; the registration statement on Form S-8, File No.  333-202681, filed by the Registrant on March 12, 2015, relating to the Registrant’s 2013 Stock Incentive Plan; the registration statement on Form S-8, File No.  333-210028, filed by the Registrant on March 9, 2016, relating to the Registrant’s 2013 Stock Incentive Plan; the registration statement on Form S-8, File No.  333-216638, filed by the Registrant on March 13, 2017, relating to the Registrant’s 2013 Stock Incentive Plan; the registration statement on Form S-8, File No.  333-223612, filed by the Registrant on March 13, 2018, relating to the Registrant’s 2013 Stock Incentive Plan; the registration statement on Form S-8, File No.  333-229878, filed by the Registrant on February 26, 2019, relating to the Registrant’s 2013 Stock Incentive Plan; and the registration statement on Form S-8, File No.  333-236707, filed by the Registrant on February 27, 2020, relating to the Registrant’s 2013 Stock Incentive Plan and 2013 Employee Stock Purchase Plan.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8.

Exhibits.

 

Number    Description
4.1    Restated Certificate of Incorporation of the Registrant (Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-35945) on August 4, 2020 and incorporated herein by reference)
4.2    Amended and Restated By-Laws of the Registrant (Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-187982), and incorporated herein by reference)

 

- 1 -

5.1    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant
23.1    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)
23.2    Consent of Ernst & Young LLP
24.1    Power of attorney (included on the signature pages of this registration statement)
99.1    2013 Stock Incentive Plan, as amended on March  24, 2020 (Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No.  001-35945) on May 4, 2020 and incorporated herein by reference)
99.2    2013 Employee Stock Purchase Plan (Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-187982), and incorporated herein by reference)

 

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 23rd day of February, 2021.

 

EPIZYME, INC.
By:  

/s/ Robert B. Bazemore

Robert B. Bazemore
President and Chief Executive Officer

 

- 1 -

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Epizyme, Inc., hereby severally constitute and appoint Robert B. Bazemore and Paolo Tombesi, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Epizyme, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature    Title   Date

 

   

 

  

 

/s/ Robert B. Bazemore

    President, Chief Executive Officer, Director   February 23, 2021
Robert B. Bazemore    (Principal Executive Officer)  

/s/ Paolo Tombesi

    Chief Financial Officer   February 23, 2021
Paolo Tombesi    (Principal Financial Officer)  

/s/ Joseph Beaulieu

    Corporate Controller and Treasurer   February 23, 2021
Joseph Beaulieu    (Principal Accounting Officer)  

/s/ Andrew R. Allen

    Director   February 23, 2021
Andrew R. Allen, M.D., Ph.D.     

/s/ Kenneth Bate

    Director   February 23, 2021
Kenneth Bate     

/s/ Grant Bogle

    Director   February 23, 2021
Grant Bogle     

/s/ Kevin T. Conroy

    Director   February 23, 2021
Kevin T. Conroy     

/s/ Michael F. Giordano

    Director   February 23, 2021
Michael F. Giordano, M.D.     

/s/ Carl Goldfischer

    Director   February 23, 2021
Carl Goldfischer, M.D.     

/s/ Pablo Legorreta

    Director   February 23, 2021
Pablo Legorreta     

/s/ David M. Mott

    Director   February 23, 2021
David M. Mott     

/s/ Victoria Richon

    Director   February 23, 2021
Victoria Richon